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ABSTRACT Current therapeutic options for cryptococcal meningitis are limited by
toxicity, global supply, and emergence of resistance. There is an urgent need to de-
velop additional antifungal agents that are fungicidal within the central nervous sys-
tem and preferably orally bioavailable. The benzimidazoles have broad-spectrum an-
tiparasitic activity but also have in vitro antifungal activity that includes Cryptococcus
neoformans. Flubendazole (a benzimidazole) has been reformulated by Janssen Phar-
maceutica as an amorphous solid drug nanodispersion to develop an orally bioavail-
able medicine for the treatment of neglected tropical diseases such as onchocercia-
sis. We investigated the in vitro activity, the structure-activity-relationships, and both
in vitro and in vivo pharmacodynamics of ﬂubendazole for cryptococcal meningitis.
Flubendazole has potent in vitro activity against Cryptococcus neoformans, with a
modal MIC of 0.125 mg/liter using European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) methodology. Computer models provided an insight into the
residues responsible for the binding of ﬂubendazole to cryptococcal -tubulin. Rapid
fungicidal activity was evident in a hollow-ﬁber infection model of cryptococcal
meningitis. The solid drug nanodispersion was orally bioavailable in mice with
higher drug exposure in the cerebrum. The maximal dose of ﬂubendazole (12
mg/kg of body weight/day) orally resulted in an 2 log10CFU/g reduction in fungal
burden compared with that in vehicle-treated controls. Flubendazole was orally bio-
available in rabbits, but there were no quantiﬁable drug concentrations in the cere-
brospinal ﬂuid (CSF) or cerebrum and no antifungal activity was demonstrated in ei-
ther CSF or cerebrum. These studies provide evidence for the further study and
development of the benzimidazole scaffold for the treatment of cryptococcal menin-
gitis.
KEYWORDS Cryptococcus neoformans, cryptococcal meningoencephalitis,
benzimidazole, ﬂubendazole, -tubulin, antifungal agents, cryptococcal, meningitis,
pharmacodynamics, pharmacokinetics, tubulin
Cryptococcal meningoencephalitis (here referred to as meningitis) is a common andlethal disease in immunosuppressed patients (1, 2). This disease is predominately
associated with advanced HIV infection and has the highest incidence in low- to
middle-income countries (1). The number of effective agents is despairingly small (3).
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All available induction and maintenance regimens are constructed with three antifun-
gal agents: amphotericin B (AmB), ﬂucytosine (5FC), and ﬂuconazole (4). Each of these
compounds has signiﬁcant adverse effects that include infusional toxicity (AmB), neph-
rotoxicity (AmB [5]), bone marrow suppression (AmB and 5FC [5, 6]), and hepatotoxicity
(ﬂuconazole and 5FC [7]). Moreover, there are signiﬁcant inherent limitations that
include fungistatic effects (ﬂuconazole [8]) and the potential emergence of drug
resistance (ﬂuconazole and 5FC [9–11]). Thus, there is an urgent imperative to develop
new agents. Orally bioavailable agents are particularly important given the predomi-
nance of this disease in resource-constrained settings.
During the process of screening a compound library against fungal pathogens, it
was noted by us (Megan Truong and Ian Charles) that ﬂubendazole has potent in vitro
activity against Cryptococcus neoformans. A literature search revealed other members of
the benzimidazole class (e.g., albendazole and mebendazole) of antiparasitic agents
had previously been demonstrated to have potent in vitro activity against Cryptococcus
neoformans, with MICs of 0.16 to 0.45 mg/liter (12, 13). The pharmacological target of
the benzimidazoles against Cryptococcus neoformans is -tubulin (14). The antifungal
activity of parenterally administered ﬂubendazole in a murine model of cryptococcal
meningitis was conﬁrmed by us in a series of preliminary experiments. Concurrently, we
became aware of the efforts by Janssen Pharmaceutica to develop a new orally
bioavailable formulation of ﬂubendazole that may be active against ﬁlariasis and
onchocerciasis. The potential value of this new formulation as an oral medicine for the
treatment of cryptococcal meningitis in resource-poor health care settings was there-
fore evident.
Here we describe the in vitro activity, putative structure-activity relationships, and in
vivo pharmacokinetic-pharmacodynamic (PK-PD) relationships of ﬂubendazole against
Cryptococcus neoformans. A hollow-ﬁber infection model of cryptococcal meningitis
was developed as a ﬁrst step for exploring dose exposure-response relationships.
Subsequently, two extensively used and well-characterized laboratory animal models of
cryptococcal meningitis were used to provide the experimental foundation for the
potential use of oral formulations of ﬂubendazole or its congeners for the treatment of
a neglected infection of global signiﬁcance.
RESULTS
In vitro studies. Flubendazole displayed potent in vitro activity (MICs of 0.06 to 0.25
mg/liter [Table 1]) against C. neoformans. The MICs were comparable when European
Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Labora-
tory Standards Institute (CLSI) methodologies were used.
The ﬂubendazole 50% inhibitory concentration (IC50) against porcine tubulin was
2.38 M. Other known tubulin inhibitors display similar efﬁcacies in this assay (e.g.,
colchicine has an IC50 of 1.15 M [unpublished data], paclitaxel has an IC50 of 3.9 M
[15], and vinblastine has an IC50 of 5.3 M [15]). These data are consistent with the
known mechanism of action of ﬂubendazole.
An in vitro drug metabolism and pharmacokinetics (DMPK) assessment of commer-
cially available ﬂubendazole powder conﬁrmed a favorable log of distribution coefﬁ-
cient at pH 7.4 (logD7.4) of 2.9. Plasma protein binding was 90.6%, and there was low
metabolic turnover (human microsomal intrinsic clearance  44 l/min/mg and rat
hepatic intrinsic clearance  39 l/min/106 cells). However, aqueous solubility was
poor (0.8 M), which is characteristic of the benzimidazoles. This in vitro DMPK
TABLE 1MIC distributions of ﬂubendazole against C. neoformans isolates using CLSI and
EUCAST methodologies
Methodology No. of strains
No. of isolates with MIC (mg/liter) of:
0.03 0.06 0.125 0.25 0.5
EUCAST 50 1 19 25 5 0
CLSI 50 2 40 8 0 0
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assessment was consistent with subsequent in vivo observations (see below). Poor
aqueous solubility limits absorption through the gut, but once in the bloodstream,
ﬂubendazole has favorable pharmacokinetic properties (e.g., ability to pass through cell
membranes, low metabolism, and high concentrations of free drug) that enable it to
reach the effect site.
Docking studies. There were two principal noncovalent binding interactions be-
tween ﬂubendazole and the homology model of C. neoformans -tubulin. First, the
hydroxyl group of serine 350 (Ser350) acts as a hydrogen bond donor and binds the
ketone oxygen of ﬂubendazole (Fig. 1A). Second, asparagine 247 (Asn247) acted as a
hydrogen bond donor via the primary amide with the ketone of the carbamate on
ﬂubendazole, but it also acted as a hydrogen bond acceptor through the primary
carbonyl group of Asn247 and the N-H on the benzimidazole core. There were also
several hydrophobic interactions deeper in the binding pocket that involved the
benzene ring and the ﬂuorine of ﬂubendazole.
Docking studies of ﬂubendazole and human -tubulin (Fig. 1B) showed that both
the N-H of the benzimidazole core and the N-H of the carbamate are hydrogen bond
donors (Fig. 1B) to the primary amide of the side chain of Asn247. As for the C.
neoformans interaction, there were hydrophobic interactions present from the para-
substituted benzene and the hydrophobic binding pocket. There was a lack of a
hydrogen bond acceptor role from the ketone oxygen. This is due to the replacement
of Ser350 from the C. neoformans active site with lysine 350 (Lys350) in humans.
Hollow-ﬁber infection model of cryptococcal meningoencephalitis. Rapid fun-
gicidal activity was observed in the hollow-ﬁber infection model. Controls grew from an
initial density of approximately 6 log10 CFU/ml to 8 to 9 log10 CFU/ml (Fig. 2). Following
the administration of ﬂubendazole there was a progressive decline in the fungal density
in the hollow ﬁber in all arms. There was an exposure-dependent decline in fungal
burden.
FIG 1 (A and B) Homology model of ﬂubendazole docked with both C. neoformans (A) and human (B) -tubulin. Red sphere, hydrogen
bond donors; blue sphere, hydrogen bond acceptors; yellow sphere, hydrophobic interactions. (C and D) The docking pose is
visualized with PyMOL. Protein is shown as a surface representation colored 40% transparent light blue. Flubendazole is represented
as sticks composed of carbon (light blue), hydrogen (white), nitrogen (dark blue), oxygen (red), and ﬂuorine (cyan). Binding site
residues selected around 4 Å are represented as sticks with carbon (green), nitrogen (blue), oxygen (red), and sulfur (yellow).
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Preliminary studies to demonstrate in vivo efﬁcacy of ﬂubendazole. There was
no demonstrable antifungal effect of orally administered ﬂubendazole as a pure
compound when formulated with sterile distilled water, 0.05% polysorbate 80 in
phosphate-buffered saline (PBS), 5% dimethyl sulfoxide DMSO, 10% polyethylene
glycol 400 (PEG400), or 85% hydroxyl-propyl--cyclodextrin (data not shown). Anti-
fungal activity could be established only when pure ﬂubendazole was formulated with
polysorbate 80 (Tween 80) and injected subcutaneously (s.c.) to form a depot. Presum-
ably, formulation with polysorbate 80 solubilized ﬂubendazole to an extent that
enabled it to become systemically bioavailable. However, this was observed only when
ﬂubendazole was administered s.c. This parenteral regimen resulted in a modest
reduction in fungal burden, 1 to 2 log10 CFU/g, compared with that in vehicle-treated
controls (data not shown). A limited PK study with concentrations measured at a single
time point the end of the experiment also conﬁrmed that ﬂubendazole concentrations
were quantiﬁable in plasma and the cerebrum of mice (data not shown).
These preliminary pharmacokinetic and pharmacodynamic data provided the im-
petus for further detailed experiments examining the pharmacodynamics of a new
orally bioavailable solid drug nanodispersion against Cryptococcus neoformans devel-
oped by Janssen.
Pharmacokinetic and pharmacodynamic studies of the ﬂubendazole nanofor-
mulation in mice. When ﬂubendazole was formulated as a solid drug nanodispersion,
it was rapidly absorbed after oral dosing and plasma concentrations were readily
quantiﬁable at the ﬁrst sampling point (i.e., 0.5 h postdose [Fig. 3]). The pharmacoki-
netics was linear, with biexponential clearance from the bloodstream with mean and
FIG 2 Hollow-ﬁber infection model of cryptococcal meningitis. (A) Pharmacokinetics of ﬂubendazole
with the three arms with intended peak concentrations of 1.25, 2.5, and 10 mg/liter; (B) pharmacody-
namics in response to ﬂubendazole administered at various doses q24h. Therapy was initiated 24 h
postinoculation, after which time Cryptococcus had grown from 6 log10 CFU/ml to 8 log10 CFU/ml.
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median values of 0.039 and 0.026 liter/h, respectively (Fig. 3). The pharmacokinetic
parameters are summarized in Table 2. There was rapid and extensive distribution of
drug to the cerebrum in mice, and concentrations of ﬂubendazole were consistently
higher than those observed in plasma. The ratio of the area under the curve (AUC) for
serum and the AUC for the cerebrum was 1:4.44.
Flubendazole had a signiﬁcant and discernible antifungal effect in mice. Use of the
highest dose in this study (12 mg/kg) resulted in approximately a 2- to 3-log reduction
FIG 3 Flubendazole pharmacokinetics in mice and rabbits. (A) Mouse plasma concentration-time proﬁles
following the administration of ﬂubendazole at 2, 4, 6, 8, and 12 mg/kg. (B) Mouse concentration-time
proﬁles in the brain following the administration of ﬂubendazole at 2, 4, 6, 8, and 12 mg/kg. Data are
means  SDs for 3 mice. (C) Plasma pharmacokinetics in the serum for individual rabbits receiving 6
mg/kg/day (broken lines and solid triangles) and 22.5 mg/kg (solid lines and solid squares).
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in fungal burden relative to that of controls (Fig. 4). This regimen was limited by
maximum permissible volumes for oral administration for mice (i.e., 20 ml/kg). In a
single experiment in which the effect of 6 mg/kg every 12 h (q12h; i.e., 12 mg/kg/day)
was compared to that of 12 mg/kg/day, there was no difference in antifungal effect
TABLE 2 Parameter values from the PK-PD model ﬁtted to mice
Parametera Mean Median SD
Ka (h1) 11.312 14.895 6.594
SCL/F (liters/h) 0.039 0.026 0.031
Vc/F (liters) 0.051 0.069 0.033
Kcp (h1) 15.741 15.404 6.806
Kpc (h1) 16.997 16.915 5.962
Kcb (h1) 3.446 0.594 4.709
Kbc (h1) 0.056 0.056 0.030
Kgmax (log10 CFU/g/h) 0.107 0.098 0.025
Hg 10.338 5.096 9.782
C50g (liters/h) 2.036 1.681 1.517
POPMAX (CFU/g) 982,934,669.178 427,055,621.187 2,281,967,059.602
IC (CFU/g) 102.255 116.462 60.966
Vb/F (liters) 0.277 0.146 0.335
aKa is the ﬁrst-order rate constant collecting the gut and the central compartment; SCL/F is the apparent
clearance of ﬂubendazole from the central compartment; Vc/F and Vb/F are the apparent volumes of the central
compartment and brain, respectively; Kcp, Kpc, Kcb, and Kbc are the ﬁrst-order intercompartmental rate constants;
and Kgmax is the maximal rate of cryptococcal growth. POPMAX is the maximum theoretical fungal density. C50g
is the concentrations of ﬂubendazole that induce half-maximal effects on growth. Hg is the slope function for
the effect of ﬂubendazole on growth. IC is the density of Cryptococcus immediately postinoculation.
FIG 4 Pharmacodynamics of ﬂubendazole in a murine model of cryptococcal meningitis. Flubendazole was administered orally once daily. Data (open squares)
are means  SDs for 3 mice. The solid line is the ﬁt of the population predicted pharmacokinetic-pharmacodynamic model. The maximally administered dose
in this study (12 mg/kg/day) slowed but did not prevent fungal growth in the brain.
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(data not shown). This is preliminary evidence that the AUC is likely to be the
dynamically linked index for ﬂubendazole against Cryptococcus neoformans.
Pharmacokinetic and pharmacodynamic studies with rabbits. The PK in rabbits
was linear, with a concentration-time proﬁle similar to that observed in mice. The
plasma concentration-time proﬁles in rabbits had a similar shape to those of mice but
were lower for the dosages used in this study. Despite readily quantiﬁable plasma
concentrations, there were no quantiﬁable drug concentrations in either the cerebro-
spinal ﬂuid (CSF) or the cerebrum in rabbits at the time of sacriﬁce.
There was no demonstrable antifungal effect in rabbits receiving 6 mg/kg/day.
There may have been some effect in rabbits receiving 22.5 mg/kg q24h, but if present,
the effect was small, and these assessments were limited by the use of few animals.
There were no statistically signiﬁcant differences in the area under the concentration
(log10 CFU/g)-time curve for each regimen, even though this may be a relatively
insensitive test of antifungal effect. Furthermore, there was no difference in the fungal
burden in the cerebrum at the end of the experiment for any of the groups of rabbits
used in this study (Fig. 5).
DISCUSSION
When given subcutaneously, ﬂubendazole has striking activity in laboratory animal
models of ﬁlarial diseases such as onchocerciasis and lymphatic ﬁlariasis (16). Janssen
developed a novel amorphous solid drug nanodispersion to provide a potential new
therapeutic option for patients with these neglected tropical diseases. The systemic
FIG 5 Pharmacodynamics of ﬂubendazole in a rabbit model of cryptococcal meningitis. (A) Time course of fungal burden in the CSF of untreated controls; (B)
time course of fungal burden in the CSF rabbits treated with ﬂubendazole at 6 mg/kg q24h orally; (C) time course of fungal burden in the CSF rabbits treated
with ﬂubendazole at 22.5 mg/kg q24h orally; (D) fungal burden in the cerebrum of rabbits at the end of the experiment (288 h postinoculation and after 10
days of treatment with ﬂubendazole). There are no differences in the three groups (P  0.464, analysis of variance).
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drug exposure that was enabled by the new formulation mandated Good Laboratory
Practice (GLP) toxicology studies before progression to early-phase clinical studies. It
was already known that ﬂubendazole is clastogenic (i.e., induces chromosomal break-
ages) and aneugenic (i.e., induces aneuploidy), as well as embryotoxic (17). GLP
toxicology studies were performed by Janssen with rats (5, 15, and 30 mg/kg/day in
male rats and 2.5, 5, and 10 mg/kg/day in female rats) and dogs (20, 40, and 100
mg/kg/day) for 2 weeks. These experiments showed evidence of toxicity related to the
pharmacological activity of ﬂubendazole in the gastrointestinal tract, lymphoid system,
and bone marrow, as well as testicular toxicity in both rats and dogs. In dogs, liver
toxicity was also observed. As a result, the development program was stopped based
on an unacceptable risk/beneﬁt proﬁle in humans. This also halted our own efforts
to develop ﬂubendazole for cryptococcal meningitis.
Flubendazole has striking in vitro activity against Cryptococcus neoformans that was
evident in the MIC testing and the pharmacodynamic studies in the hollow-ﬁber
infection model. There was modest antifungal activity in the murine model, which is not
as prominent as that previously described by us for ﬂuconazole, amphotericin B
deoxycholate, or liposomal amphotericin B (8, 18, 19). There was no unequivocal
antifungal activity in the rabbit model of cryptococcal meningoencephalitis, which is
largely explained by the absence of detectable ﬂubendazole concentrations in the
cerebrum or CSF (despite readily quantiﬁable plasma concentrations). The in vitro
susceptibility testing and data from the hollow-ﬁber model suggest that ﬂubendazole
is highly potent and fungicidal if able to reach its fungal target in sufﬁcient concen-
trations. The diminished activity in mice (relative to historical controls) and absence of
effect in rabbits (with nonquantiﬁable concentrations in the cerebrum and CSF) further
support this conclusion. Hence, successful exploitation of the benzimidazole backbone
requires careful attention to physiochemical properties that promote absorption across
the gut and the ability to partition into subcompartments of the central nervous system
(CNS).
Flubendazole did not display a degree of in vivo activity comparable to those of
other ﬁrst-line agents for cryptococcal meningitis (i.e., ﬂuconazole and amphotericin B
formulations). Even if the safety proﬁle was not problematic, there is insufﬁcient prima
facie evidence from either the murine or rabbit model to further study ﬂubendazole as
monotherapy for induction therapy in phase II clinical studies. Nevertheless, additional
approaches, such as combination with other antifungal agents for induction therapy
and/or use as longer-term consolidation and maintenance therapy, may have been
possible.
The potential of derivatives of ﬂubendazole to be useful human medicines depends
on the differential activity between cryptococcal and human proteins. Characterization
of the -tubulin genes of C. neoformans has been undertaken, and two C. neoformans
-tubulin genes (TUB1 and TUB2) have been identiﬁed. TUB1 was identiﬁed as the
primary target of the benzimidazole class of compounds through gene characterization
and expression (14). There is 90% homology between fungal TUB1 and human
-tubulin, although the former has not been crystallized and this has prevented
deﬁnitive structure-activity-relationship docking studies. The ability to develop new
agents based on a benzimidazole scaffold or to further exploit -tubulin as a pharma-
cological target will depend on the degree of differential activity of a benzimidazole
with these proteins. The differential binding identiﬁed through the docking and
homology modeling of both human -tubulin (20) and C. neoformans var. grubii
serotype A (strain H99) -tubulin (14) to the Bos Taurus 1SA0 -tubulin crystal structure
implies an increased number of binding interactions with C. neoformans -tubulin. This
may provide the potential to exploit this differential binding to establish a favorable
therapeutic index. It is also worth emphasizing that the benzimidazoles may have
additional targets beyond -tubulin that have the further potential to provide differ-
ential activity between human and fungal proteins, but this requires further investiga-
tion (21–24).
The potential utility of congeners of ﬂubendazole now rests with medicinal chem-
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istry programs. Compounds must be synthesized that exhibit differential activity
against cryptococcal and human tubulin (if that is possible) so that there is an
acceptable safety margin and toxicity proﬁle. Furthermore, the compound must be able
to traverse the gut (compounds that are not orally bioavailable will be less clinically
valuable) and then the blood-brain barrier to achieve concentrations that are ideally
fungicidal. The latter will be promoted by new low-molecular-weight, lipophilic com-
pounds that are not substrates for efﬂux pumps such as P-glycoprotein. This will
undoubtedly also require the use of novel formulation technologies to ensure that
compounds that are poorly soluble can become useful agents for disseminated infec-
tions.
MATERIALS AND METHODS
Drug. Flubendazole that was used for determination of MICs, hollow-ﬁber experiments, and prelim-
inary murine experiments was purchased from Sigma. Subsequently, deﬁnitive pharmacokinetic-
pharmacodynamic experiments that were performed with orally administered ﬂubendazole used a solid
drug nanodispersion formulation developed by Janssen Pharmaceuticals (batch BREC-1113-070; Janssen
Pharmaceuticals). The stability of this formulation in liquid and solid phases was conﬁrmed for 1 and 6
months, respectively.
A 10-mg/ml methylcellulose (4,000-cps) stock solution (100-ml batch) was prepared from a dispersion
of 1 g of methylcellulose (4,000 cps) with stirring into 70 ml of demineralized water heated to 70°C to
80°C. The solution was stirred for at least 15 min, followed by the addition of 20 ml of demineralized
water. The mixture was stirred until it reached room temperature and was then made up to 100 ml with
demineralized water. A total of 50 ml of 6-mg/ml spray-dried powder suspension was then prepared (this
corresponds to 0.6 mg/ml of ﬂubendazole as the active dose in 0.5% methylcellulose). A total of 24.70
g of demineralized water was added to a 50-ml clear glass vial. A total of 0.30 g of spray-dried drug was
added to the vial, which was then closed with a stopper. The vial was vortexed and then homogenized
using a Polytron disperser. A 25-ml stock solution of methylcellulose (4,000 cps) was added and the vial
was vortexed. The suspension was refrigerated at 5°C until dosing for a maximum of 14 days. Prior to
dosing, the suspension was vortexed.
Strains. The initial in vitro susceptibility testing was performed with H99 (ATCC 208821). An
additional 49 clinical isolates were obtained from the National Centre for Microbiology Instituto de Salud
Carlos III, Madrid, Spain (courtesy of Ana Alastruey-Izquierdo and Manual Cuenca-Estrella). These isolates
were identiﬁed to the species level using standard microbiological techniques.
MICs. The MIC of ﬂubendazole against H99 (ATCC 208821) and the 49 isolates was estimated using
methodology of the European Committee on Antimicrobial Susceptibility Testing (EUCAST [25]) and the
Clinical and Laboratory Standards Institute (CLSI [26]). The endpoint for MIC determination using was
50% for both the EUCAST and CLSI methods. MICs were performed in triplicate.
Porcine tubulin polymerization assay. Porcine tubulin is generally used as a surrogate for human
tubulin because of its high degree of homology (95%) (27). In the studies described here, this assay was
used to determine the extent of interaction between ﬂubendazole and its putative target; it has also
been used for assessment of the binding of antineoplastic agents (28, 29). The commercially available
porcine tubulin assay (BK011P; Cytoskeleton, Inc., Denver, CO) quantiﬁes the time-dependent polymer-
ization of tubulin to microtubules and thus the ability of tubulin inhibitors to disrupt this process.
The porcine tubulin assay was performed according to the manufacturer’s instructions. Brieﬂy, the
96-well assay plate was prewarmed to 37°C prior to use. Five microliters of test compound(s) and controls
at 0, 1.25, 2.5, 5, and 10 M were aliquoted into each well and prewarmed for 1 min. Colchicine and
DMSO were used as positive and negative controls, respectively. Polymerization was initiated by mixing
45 l of reaction buffer that contained 2 mg/ml of puriﬁed porcine brain tubulin, 10 M ﬂuorescent
reporter, PEM buffer (80 mM PIPES, 0.5 mM EGTA, 2 mM MgCl2 [pH 6.9]), 1 mM GTP, and 20.3% glycerol.
Tubulin polymerization was followed by an increase in ﬂuorescence intensity due to the incorporation
of a ﬂuorescence reporter into microtubules as polymerization occurred. The change in ﬂuorescence was
measured using an excitation and emission wavelength of 360 nm and 450 nm, respectively, every 1 min
for 1 h at 37°C using a Varioskan multimode plate reader (Thermo scientiﬁc Inc.). All data points were
acquired in triplicate, and IC50s were calculated with GraphPad Prism. The IC50 was deﬁned as the drug
concentration required to inhibit tubulin polymerization by 50% compared with the negative control.
Homology modeling and docking studies. While the amino acid sequence of cryptococcal
-tubulin is known (74% homology with human -tubulin), the protein has not been crystallized. A
homology model was therefore developed to investigate differential binding modes of ﬂubendazole
within C. neoformans and human -tubulin. Molecular modeling (Modeler version 9.14; https://salilab
.org/modeller/) of both human -tubulin (20) and C. neoformans var. grubii serotype A (strain H99)
-tubulin (14) was undertaken using the Bos Taurus 1SA0 -tubulin crystal structure (identity, 364/447
[81.4%]; similarity, 405/447 [90.6%]).
Virtual ﬂubendazole was built in the molecular modeling software Spartan (Wavefunction Inc., Irvine,
CA) and energy minimized. Flubendazole was then subjected to a piecewise linear potential (ChemPLP)
docking protocol (a scoring function to provide conﬁdence in the docking pose adopted by the
molecule), consisting of 10 genetic algorithm (GA) runs before visualization using the molecular
visualization system PyMOL with the top scoring compound depicted in Fig. 1. The active-site binding
interactions were selected by identifying those amino acid residues within 4 Å of ﬂubendazole when
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docked into the -tubulin binding site. Polar contacts between ﬂubendazole and the surrounding amino
acids were identiﬁed, which aided in the identiﬁcation of hydrogen bonding interactions that are key in
determining the efﬁcacy of a drug against its pharmacological target.
Finally, hydrogen bond donor interactions as well as hydrophobic interactions were identiﬁed using
the pharmacophore (i.e., an abstract description of molecular features that in this case are necessary for
molecular recognition of ﬂubendazole by -tubulin) search software ZINCPharmer (30) at 4 Å for
hydrogen bonding interactions and 6 Å for hydrophobic interactions.
Hollow-ﬁber model of cryptococcal meningoencephalitis. A new hollow-ﬁber infection model
was developed to investigate the in vitro pharmacodynamics of ﬂubendazole against C. neoformans. The
same cartridges (FiberCell Systems, Frederick, MD) and conﬁguration as previously described for bacterial
pathogens was used (see, for example, reference 31). The extracapillary space of each cartridge was
inoculated with 40 ml of a suspension containing 6 log10 CFU/ml of C. neoformans var. grubii (ATCC
208821; H99). Yeast extract-peptone-dextrose (YPD) medium was pumped from the central compartment
through the cartridge and back again using a peristaltic pump (205 U; Watson-Marlow, United Kingdom).
The hollow-ﬁber infection model was incubated at 37°C in ambient air. The time course of fungal growth
was determined by removing 1 ml from the extracapillary space of the cartridge and plating serial 10-fold
dilutions to YPD agar.
The relationship between ﬂubendazole exposure and its effect was explored using a range of drug
exposures. Since there is no information on the pharmacokinetics of ﬂubendazole in humans, we
attempted to produce AUCs that were comparable to those observed in mice. Various doses of
ﬂubendazole were administered q24h by infusion over 1 h for 8 days to the central compartment using
a programmable syringe driver (Aladdin pump; World Precision Instruments, United Kingdom). There was
a 24-h delay in the initiation of ﬂubendazole therapy postinoculation. To generate ﬁrst-order pharma-
cokinetics, fresh YPD medium was pumped into the central compartment and the same volume of
drug-containing medium was simultaneously removed and discarded. Positive controls of currently
licensed agents were not studied in these experiments.
Murine model of cryptococcal meningoencephalitis. A previously described (8) and well-
characterized murine model of cryptococcal meningitis was used to investigate the pharmacodynamics
of ﬂubendazole. All laboratory animal experiments were performed under UK Home Ofﬁce project license
PPL40/3630 and were approved by the University of Liverpool’s Animal Welfare Ethics Review Board.
Male CD1 mice were purchased from Charles River and were 20 to 30 g at the time of experimentation.
An inoculum of 3  108 CFU in 0.25 ml was used for each mouse. Groups of mice (n  3) were serially
sacriﬁced throughout the experimental period. The brains were removed and homogenized. Serial
10-fold dilutions were plated to YPD agar supplemented with chloramphenicol to enumerate the total
fungal burden. Plates were incubated in air at 30°C for at least 48 h.
Studies of pharmacokinetics and pharmacodynamics of ﬂubendazole in mice. Preliminary
evidence for the efﬁcacy of ﬂubendazole was obtained by dissolving pure compound in a variety of
excipients that included cyclodextrin (F2G; Eccles, UK), DMSO (5%), and polysorbate 80 (10%) and
injecting it subcutaneously q24h. Ultimately, only s.c. injection with Tween 80 showed any effect. This
experiment provided the impetus to further examine the orally bioavailable formulation developed by
Janssen (see above).
The pharmacokinetics of oral ﬂubendazole was determined with two independently conducted
experiments. Treatment was initiated 24 h postinoculation. Doses of 2 to 12 mg/kg were used. Only the
ﬁrst dosing interval was studied. A serial-sacriﬁce design was used with groups of 3 mice that were
sacriﬁced at 0.5, 1, 2, 8, and 24 h postinoculation.
The pharmacodynamics of oral ﬂubendazole was estimated over the course of three separate
independently conducted experiments. Groups of 3 mice were sacriﬁced at 2, 24, 48, 96, 144, and 168
h postinoculation. Dose ﬁnding studies were performed using ﬂubendazole at 2, 4, 6, 8, and 12 mg/kg
q24h orally. The upper dosage was limited by the volume restrictions for mice imposed by Home Ofﬁce
project license PPL40/3630. A fourth experiment compared 12 mg/kg q24 with 6 mg/kg q12h to examine
whether more fractionated regimens provided any additional antifungal effect.
Rabbit model of cryptococcal meningitis. A previously described and well-characterized rabbit
model of cryptococcal meningoencephalitis (32) was used to further investigate the pharmacodynamics
of ﬂubendazole. Male New Zealand White rabbits were purchased from Harlan. Rabbits weighed 2.5 to
3 kg at the time of experimentation. Rabbits were immunosuppressed intramuscularly with hydrocorti-
sone at 10 mg/kg on day 1 relative to infection and then daily throughout the experiment.
Cryptococcal meningoencephalitis was induced with the intracisternal inoculation of 0.25 ml of a
suspension containing 3.8  108 CFU/ml under general anesthesia (induced with medetomidine and
ketamine). This inoculum results in progressive infection that manifests as an increase in fungal burden
in the CSF and reproducible encephalitis. There was minimal clinical disease with no demonstrable
neurological signs in the experimental period. Mortality always occurred in the context of cisternal
tapping and repeated anesthesia rather than from progressive infection.
Studies of pharmacodynamics and pharmacokinetics in rabbits. PK-PD relationships in the rabbit
were estimated in two independently conducted experiments including 6 rabbits in each. Rabbits were
placed under general anesthesia for removal of CSF via intracisternal tapping at 48 h intervals. Over the
course of the two experiments there were 3 controls (1 rabbit died after being tapped); ﬂubendazole was
given at 6 mg/kg q24h (n  6) and 22.5 mg/kg q24h (n  6). The maximum dosage that was used was
limited by the formulation provided by Janssen and the limits of oral gavage in rabbist (15 ml/kg/day).
Treatment was initiated 48 h postinoculation and continued for 10 days, after which time all rabbits were
sacriﬁced. Thus, the total duration of the experiment was 288 h.
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Measurement of ﬂubendazole concentrations using LC-MS/MS. Flubendazole concentrations in
all matrices were measured using validated ultrahigh-performance liquid chromatography-tandem mass
spectrometry (LC-MS/MS) implemented on an Agilent 6420 triple quad mass spectrometer and an
Agilent 1290 inﬁnity LC system (Agilent Technologies UK Ltd., Cheshire, UK). Flubendazole was extracted
by protein precipitation by adding 300 l of a 50:50 mix of acetonitrile and methanol that contained the
internal standard [6,7-dimethyl-2,3-di(2-pyridyl) quinoxaline; Sigma-Aldrich, Dorset, UK] at a ﬁnal con-
centration of 1 mg/liter to 30 l of each matrix.
The extraction was performed in 96-well Sirocco protein precipitation plates (Waters, UK). Samples
were then shaken for 2 min and extracted using a positive-pressure 96 manifold (Waters). A total of 200
l of the supernatant was removed and placed in a 96-well plate. One microliter was injected on an
Agilent a Zorbax Eclipse Plus C18 column (2.1 by 50 mm; 1.8-m particle size; Agilent Technologies UK
Ltd.). Chromatographic separation was achieved using a gradient with the starting conditions of a 60:40
mix of A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile). The ratio of A to B changed
to 20:80 over 2 min and then returned to the starting conditions (60:40) for 1 min of equilibration.
The mass spectrometer was operated in multiple reaction monitoring (MRM) scan mode in positive
polarity. The precursor ions for ﬂubendazole and the internal standard were 314.1 m/z, and 313.15 m/z,
respectively. The product ions for ﬂubendazole and the internal standard were 282.1 m/z and 284.1 m/z,
respectively. The source parameters were set as 4,000 V for capillary voltage, 350°C for gas temperature,
and 60 lb/in2 for the nebulizer gas.
The standard curve for ﬂubendazole encompassed the concentration range of 0.0005 to 8.0 mg/liter
and was constructed using the respective blank matrix. The limit of quantitation was 0.0005 mg/liter, the
coefﬁcient of variation (CV) was 12.7% over the concentration range of 0.0005 to 8 mg/liter, and the intra-
and interday variation was 12% for all matrices.
Mathematical modeling. The pharmacokinetic and pharmacodynamic data sets from mice were
modeled using the program Pmetrics (33) and the following ﬁve inhomogeneous differential equations:
XP1 B1 Ka X1 (1)
XP2 Ka X1 SCLV  X2 Kcp X2 Kpc X3 Kcb X2 Kbc X4 (2)
XP3 Kcp X2 Kpc X3 (3)
XP4 Kcp X2 Kpc X4 (4)
XP5  Kgmax 1 
X4
V Hg
C50g
Hg X4V Hg	  
1  X5POPMAX  X5 (5)
The system parameters and their units are as follows: B(1) (mg) represents the bolus input of
ﬂubendazole into the gut. Ka (h1) is the ﬁrst-order rate constant collecting the gut and the central
compartment, SCL (liters/h) is the clearance of ﬂubendazole from the central compartment, V (liters) is
the volume of the central compartment, and Kcp (h1) and Kpc (h1) are the ﬁrst-order intercompart-
mental rate constants. Kgmax (log10 CFU/g/h) is the maximal rate of cryptococcal growth. POPMAX (CFU/g)
is the maximum theoretical fungal density. C50g (mg/liter) is the concentration of ﬂubendazole that
induces half-maximal effects on growth. Hg is the slope function for growth. The initial condition (CFU/g;
not shown in the equations) is the fungal density immediately following inoculation and is estimated
along with other parameters.
Equations 1, 2, 3, and 4 are pharmacokinetic equations that describe the movement of drug from the
gut, throughout the body, and into the brain. Equation 1 describes the movement of drug from the gut.
Equation 2 describes the rate of change of ﬂubendazole in the central compartment (plasma) with
ﬁrst-order clearance and movement of drug to and from both a peripheral (unmeasured) compartment
and the cerebrum. Equations 3 and 4 describe the rate of change of drug in the peripheral and cerebral
compartments, respectively. The pharmacodynamics of ﬂubendazole against Cryptococcus neoformans is
described by equation 5, which has terms that describe the capacity-limited growth of Cryptococcus and
ﬂubendazole-induced suppression of growth. The antifungal activity in the cerebrum is primarily related
to concentrations in the cerebrum.
A similar model was used to model the PK-PD data from rabbits, but there were some differences.
First, no drug was detectable in the brain or the CSF. Therefore, we let plasma concentrations of drug
drive the antifungal effect and did not attempt to model the concentration of drug in the central nervous
system (as was the case for mice). We directly linked plasma concentrations with the antifungal effect.
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